Publication | Closed Access

1191O MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy

Phase Ii TrialMedicinePrior Checkpoint InhibitorImmune Checkpoint InhibitorPharmacotherapyCancer TreatmentOncologyRadiation OncologyLung CancerMolecular OncologyRadiologyHealth Sciences